Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

ABSTRACT: Chromatin regulators have become highly attractive targets for cancer therapy, yet many of these regulators are expressed in a broad range of healthy cells and contribute generally to gene expression. An important conundrum has thus emerged: how can inhibition of a general regulator of gene expression produce selective effects at specific oncogenes? Here we investigate how inhibition of the transcriptional coactivator BRD4 (Bromodomain containing 4) leads to selective inhibition of disease-critical oncogenes in a highly malignant blood cancer, multiple myeloma (MM). We found that BRD4 generally occupies the promoter elements of active genes together with the Mediator coactivator, but remarkably high levels of these two coactivator proteins were associated with a small set of exceptionall

ORGANISM(S): Homo sapiens

SUBMITTER: Richard Young 

PROVIDER: E-GEOD-42355 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress